Verastem, Inc. Stock

$4.15

0.24% yesterday

Nasdaq, Jun 27, 10:07 pm CET

ISIN

US92337C1045

Symbol

VSTM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Verastem, Inc. Stock price

$4.15

-16.25 79.66% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.01 0.24%

ISIN

US92337C1045

Symbol

VSTM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$228.0m

Enterprise Value

$186.0m

Net debt

$-42.1m

Cash

$117.6m

Shares outstanding

51.5m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | 9.96

EV/Sales

- | 8.12

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-28.46%

Return on Equity

452.14%

ROCE

ROIC

Debt/Equity

-2.33

Financials (TTM | estimate)

Revenue

- | $22.9m

EBITDA

- | -

EBIT

Net Income

- | $-140.2m

Free Cash Flow

$-115.2m

Growth (TTM | estimate)

Revenue

- | 129.06%

EBITDA

- | -

EBIT

Net Income

- | -7.34%

Free Cash Flow

-21.85%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -612.19%

Free Cash Flow

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Verastem, Inc. Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a Verastem, Inc. forecast:

14x Buy

93%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a Verastem, Inc. forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Verastem, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	10 10	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	33 33	8% 8% 333%
- Research and Development Expense	64 64	4% 4% 636%
EBITDA	-87 -87	6% 6% -869%
- Depreciation and Amortization	0.03 0.03	50% 50% 0%
EBIT (Operating Income) EBIT	-87 -87	6% 6% -869%
Net Profit	-97 -97	11% 11% -968%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Verastem, Inc. Stock News

Positive

Seeking Alpha

●

2 days ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Recent pipeline updates highlight promising new product candidates advancing to late-stage trials, strengthening my confidence in future growth. The company maintains a solid financial position, with strong cash reserves and prudent expense management supporting ongoing R&D initiatives. Key strengths include a diversified portfolio and robust clinical data, though regulatory risks and competiti...

Neutral

Business Wire

●

4 days ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in VS-7375-101, the U.S. Phase 1/2a clinical trial evaluating VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, in patients with advanced KRAS G12D ...

Neutral

Business Wire

●

26 days ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma...

More Verastem, Inc. News

Company Profile

Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Head office	United States
CEO	Dan Paterson
Employees	78
Founded	2010
Website	www.verastem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now